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OBJECTIVES: To determine a proﬁle of renal transplant recip-
ients (RTRs) who are at highest risk for immunosuppressant
therapy (IST) non-adherence. METHODS: Retrospective analy-
sis was performed on follow-up non-adherence data routinely
reported by transplant centers to the United Network for Organs
Sharing in the United States Renal Data System. Those who
received transplants on or after January 1, 1995, had at least 36
months of follow-up data, and did not receive a second renal
transplant were included in the analyses. Random effects logit
regression was used to estimate risk of non-adherence while con-
trolling for age, race, education, donor type, primary insurance
and IST including cyclosporine (CSA), tacrolimus (TAC), aza-
thioprine (AZA), mycophenolate mofetil (MMF) and steroids.
Association between IST non-adherence and graft failure was
also examined. RESULTS: 53,997 individuals met the inclusion
criteria. Mean age at time of transplant was 44 years (SD = 15).
Sixty percent were male, 74% were Caucasian, 29% had college
education, and 39% had living donor transplants. At time of
transplant, 5% were on Medicaid and 44% were on Medicare.
CSA, TAC, AZA, MMF and steroids were used by 61%, 34%,
13%, 72% and 97% of RTRs, respectively. About 5.5% of RTRs
were reported as non-adherent and 3% had graft failure within
36 months post-transplant. Non-adherence risk increased with
time and decreased with age (p < 0.001). RTRs who were male,
non-Caucasian, not on Medicare, or used MMF or TAC had
higher risk for non-adherence, with odds ratios (OR) of 1.4, 2.0,
1.6, 1.1, and 1.3 respectively (p < 0.05), while RTRs who used
CSA, steroids or AZA had lower risk (OR = 0.8, 0.5 and 0.7
respectively, p < 0.001). Non-adherent RTRs had higher risk for
graft failure (OR = 5.2, p < 0.001). CONCLUSION: Interven-
tions aimed at improving adherence should target younger RTRs,
male RTRs, non-Caucasian RTRs, and those not on Medicare to
reduce risk of graft failure.
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OBJECTIVES: Haemoglobin cycling is common in haemodialy-
sis patients receiving erythropoiesis-stimulating agents (ESAs). It
is uncertain whether different ESAs are associated with greater
ﬂuctuations in haemoglobin. The purpose of this study was to
compare the within-patient variability in haemoglobin levels in
haemodialysis patients receiving intravenous epoetin alfa or
intravenous darbepoetin alfa. METHODS: Data on haemodial-
ysis patients were extracted from the Renal Anaemia Manage-
ment (RAM) database from 2003 to 2004. The variance in
haemoglobin was calculated for each patient with more than one
haemoglobin observation (n = 4751). A mixed-effects analysis of
variance model was ﬁtted to the within-patient variances and
weighting was based on the number of observations minus 1 for
each patient. The model allowed the treatment comparisons to
be undertaken after taking into account the situations where
patients have data on both products and can hence act as their
own control. RESULTS: The mean within-patient variance in
haemoglobin levels for patients receiving darbepoetin alfa was
23% (95% CI: 16% to 29%) greater than that for patients
receiving epoetin alfa (p < 0.0001). The mean haemoglobin level
for patients receiving darbepoetin alfa was 11.33 g/dL (95% CI:
11.27, 11.38) compared with 11.41 g/dL (95% CI: 11.38, 11.45)
for patients receiving epoetin alfa (p = 0.008). CONCLUSION:
There was greater within-patient ﬂuctuation in haemoglobin
levels in patients receiving darbepoetin alfa compared with
epoetin alfa. The implications of haemoglobin ﬂuctuations on
patient outcomes and resource use require further study.
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OBJECTIVES: To compare the within-patient variability in
haemoglobin levels in pre-dialysis or peritoneal dialysis patients
receiving intravenous epoetin alfa or intravenous darbepoetin
alfa. METHODS: Data on pre-dialysis (n = 169) and peritoneal
dialysis (n = 162) patients were extracted from the Renal
Anaemia Management (RAM) database from 2003 to 2004. The
variance in haemoglobin was calculated for each patient with
more than one haemoglobin observation. A mixed-model was
ﬁtted to the within-patient variances and weighting was based
on the number of observations minus 1 for each patient. The
model took into account the situation where patients had data
on both agents and could therefore act as their own control.
RESULTS: The mean within-patient variance in haemoglobin
levels for pre-dialysis patients receiving darbepoetin alfa was
63% (95% CI: 1% to 163%) greater than that for patients
receiving epoetin alfa (p = 0.045). The mean haemoglobin level
for patients receiving darbepoetin alfa was 10.34 g/dL (95% CI:
9.94, 10.80) compared with 11.22 g/dL (95% CI: 10.95, 11.50)
for patients receiving epoetin alfa (p = 0.001). For peritoneal
dialysis patients, those administered darbepoetin alfa had similar
within-patient variability in haemoglobin levels compared to
those receiving epoetin alfa (darbepoetin 10% greater than
epoetin alfa, 95% CI: −28% to 66%, p = 0.7). The mean haemo-
globin level for patients receiving darbepoetin alfa was 11.49
g/dL (95% CI: 11.19, 11.78) compared with 11.16 g/dL (95%
CI: 10.81, 11.50) for patients receiving epoetin alfa (p = 0.14).
CONCLUSION: In spite of the small sample size, there was a
signiﬁcantly greater within-patient ﬂuctuation in haemoglobin
levels in pre-dialysis patients receiving darbepoetin alfa com-
pared with epoetin alfa, while no difference was seen in peri-
toneal dialysis patients. The implications of haemoglobin
ﬂuctuations on patient outcomes and resource use require further
study.
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OBJECTIVES: The objective of this study is to estimate the ﬁve-
year impact on costs associated with hospitalization in patients
under renal replacement therapy (RRT) when a shift in treatment
modality from hemodialysis (HD) to peritoneal dialysis (PD) is
assumed. METHODS: An Excel-based budget impact model
(BIM) was developed to assess the impact of a shift in treatment
modality share. Model inputs included dialysis modality shares,
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patient years at risk, hospital days and costs of hospitalization
per patient per year per modality, annual growth rate of end
stage renal disease (ESRD), and years to reach new modality
shares. The study used data from the monthly clinical report
(MCR) for the year 2005 in the network of renal clinics of Renal
Therapy Services (RTS) Colombia. The entire hospitalization
events were included. Cost data were obtained from a renal unit
from the RTS network and imputed on a daily basis. RESULTS:
A total of 7441 patients were under RRT in the RTS network in
Colombia in 2005. 57.2% were on HD and 42.8% on PD. For
patients on PD, 79.5% were on continuous ambulatory PD
(CAPD) and 20.5% on automated PD (APD). The average daily
costs of a hospital admission per patient in 2006 US dollars were
estimated to be $334 for HD, $175 for CAPD, and $206 for
APD. The annual growth rate of ESRD was estimated to be 8%.
A hypothesized shift of 5% of the patients in treatment modal-
ity from HD to PD in a ﬁve-year period represented a cumu-
lative net savings of $2,332,423 in total hospital costs. 
CONCLUSION: This simulation model analysis indicates that
an increased use of PD results in substantial savings in the hos-
pital costs of patients in RRT, and in a signiﬁcant impact on the
budget of the health care system.
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OBJECTIVES: Brazil has a very developed renal transplantation
program, ﬁnanced entirely by the government. Tacrolimus is one
of the most used drugs to prevent graft rejection. A clinical study,
presented during the 2006 Mexican National Transplantation
Congress, raised some concerns about non-interchangeable
generic substitution of tacrolimus. We developed a decision-
making model that will allow the user to weigh risks and 
beneﬁts of substituting tacrolimus by a generic formulation.
METHODS: We developed a Markov model, using Monte 
Carlo simulation, describing the clinical history of post-renal
transplantation patients over a 5-year period. The model esti-
mates clinical outcomes, rejection episodes, graft loss, patients
returning to dialysis, re-transplantation, number of deaths, 
costs and cost-effectiveness (in terms of rejections avoided) 
of immunosuppressive treatment with original versus generic
tacrolimus. Transition probabilities were derived from the US
Renal Data System, the Brazilian renal transplantation program,
the above-mentioned Mexican study and international medical
literature. Local management of each health state was based on
a Delphi panel and government program costs were applied. A
3% annual discount rate was used. Sensitivity analyses were per-
formed for key parameters. RESULTS: Over a 5-year horizon
and simulating 10,000 patients in the base case scenario, origi-
nal versus generic tacrolimus generated fewer rejections (1005),
fewer patients needing dialysis (609), fewer re-transplantations
(114), fewer deaths (164), and was thus able to reduce (avoid)
total costs by 2%. A cost-effectiveness curve was derived that
illustrates the trade-off between key parameters, such as rejec-
tion rate and treatment cost. CONCLUSION: Lower treatment
costs may be offset by the impact of clinical outcomes if the
generic formulation of tacrolimus were not therapeutically
equivalent to the original. We developed a decision-analytic
model resulting in cost-effectiveness curves that illustrate the
trade-off between these risks and beneﬁts, and will enable an
informed decision-making process regarding generic substitution
of tacrolimus.
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OBJECTIVES: Icodextrin-based solutions have potential clinical
advantages over glucose-based solutions in ﬂuid and metabolic
management of diabetic end state renal disease (ESRD) patients
undergoing peritoneal dialysis (PD). The cost-effectiveness (CE)
of icodextrin-based solutions compared to glucose-based solu-
tions is not known. The purpose of the present study is to esti-
mate CE of icodextrin-based solution for peritoneal dialysis in
diabetic ESRD patients with high average and high peritoneal
transport. METHODS: A decision analytic model was developed
to estimate cost per life year gained of icodextrin-based solu-
tions. Clinical (improvement in peritoneal ultraﬁltration, reduc-
tion of extracellular ﬂuid volume, metabolic, blood pressure
control, edema, therapy related complications, and mortality)
and resource utilization (all-cause hospital admissions and
lengths of stay) data were obtained from a 12 month, multicen-
ter, open-label, randomized, clinical trial conducted in the
Mexican Institute of Social Security (IMSS) in Mexico City
where patients were assigned in one of two groups, dextrose
(GLU, n = 29) or icodextrin (ICO = 30). Cost data, expressed in
2006 US dollar, were obtained from ﬁnancial information data-
base in IMSS. Costs related to adverse events, drugs, hospital-
izations, medical care, intensive care unit and surgery were
included. Univariate and probabilistic sensitivity analyses were
performed using a Monte Carlo simulation method. RESULTS:
Clinical data indicated that icodextrin-based solution was a sig-
niﬁcant aid for the management of this population. Patients in
ICO group had lower hospital length of stay (on average 3 day)
compared to GLU group. The total per patient per year cost of
ICO group was $13,953, while that for GLU group was
$16,788. Expected cost-effectiveness ratios were $14,209 per life
year gained and $17,716 per life year gained for ICO and GLU,
respectively (p < 0.0001). ICO group was also shown to be dom-
inant in 100% of cases. CONCLUSION: Icodextrin-based solu-
tion was cost-effective in treating diabetic ESRD patients 
with high average and high peritoneal transport undergoing PD
treatment.
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) can lead
to signiﬁcant morbidity, mortality, & health care resource uti-
lization in chronic kidney disease (CKD) Stage 5 patients receiv-
ing hemodialysis. The objective of this study was to determine if
predialysis patients with SHPT experience similar clinical and
